On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent has experienced few setbacks. One came in 2023, however, when the FDA ...

Sanofi and Regeneron Pharmaceuticals drug Dupixent has won FDA approval for chronic spontaneous urticaria, introducing a new approach to the treatment of this inflammatory skin disorder.

The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than 300,000 adults and adolescents aged 12 years and ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch ...

“Dupixent is the first new targeted treatment for chronic spontaneous urticaria, or CSU, in over ten years, with pivotal trials demonstrating its ability to help patients significantly reduce ...

Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more than 300,000 adults and adolescents aged 12 years and ...